PharmaCyte Biotech (PMCB) Non-Current Debt (2012 - 2021)

PharmaCyte Biotech (PMCB) posted quarterly Non-Current Debt of $75200.0 for Q1 2021, little changed quarter-over-quarter from $75200.0 in Q4 2020.

PharmaCyte Biotech (PMCB) Non-Current Debt (2012 - 2021) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Non-Current Debt for 4 consecutive years, with $75200.0 the latest figure, recorded in Q1 2021.

In Q1 2021, Non-Current Debt changed N/A year-over-year to $75200.0; the TTM figure through Jan 2021 stood at $75200.0 (changed N/A YoY), while the FY2020 annual figure was $46282.0, changed N/A from the prior year.
Non-Current Debt held at $75200.0 in Q1 2021 per PMCB's latest filing, from $75200.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $75200.0 in Q3 2020 and bottomed at $46282.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	PharmaCyte Biotech	4.38 Mn	4.38 Mn	-	-

Download Data